Synthetic peptides for the treatment of myasthenia gravis
US6066621A · kind A · utility
5Cited by
1References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | May 23, 2000 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor .alpha.-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthenogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.